Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cytology

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    364 result(s) found for: Cytology. Displaying page 1 of 19.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2014-005553-39 Sponsor Protocol Number: 1501 Start Date*: 2015-12-29
    Sponsor Name:Karolinska University Hospital
    Full Title: Effects of Sativex on blood leukocytes in patients with lymphoma/chronic lymphocytic leukaemia
    Medical condition: Lymphoma and chronic lymphocytic leukaemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005017-71 Sponsor Protocol Number: CHOCOLATE Start Date*: 2016-04-02
    Sponsor Name:Centre François Baclesse
    Full Title: Diagnostic value of 18F-choline PET in patients with indeterminate cytology thyroid nodule : A pilot study
    Medical condition: Patient with a thyroid nodule ≥15mm with indefinite cytology according to the 2008 Bethesda classification (vesicular lesion of undetermined significance; follicular neoplasm or cell Hürthle; lesi...
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004860 10043747 Thyroid neoplasms HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-005695-15 Sponsor Protocol Number: NL56123.031.15 Start Date*: 2017-07-14
    Sponsor Name:NKI-AVL
    Full Title: Treatment of PERitoneal dissemination in Stomach Cancer patients with cytOreductive surgery and hyperthermic intraPEritoneal chemotherapy: the PERISCOPE II study
    Medical condition: Gastric cancer with peritoneal carcinomatosis or tumour positive cytology
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10017812 Gastric neoplasms malignant HLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061269 Malignant peritoneal neoplasm PT
    21.1 10042613 - Surgical and medical procedures 10057647 Cytoreductive surgery PT
    21.1 10042613 - Surgical and medical procedures 10067093 Intraperitoneal hyperthermic chemotherapy LLT
    20.0 10042613 - Surgical and medical procedures 10061965 Gastrectomy PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052171 Peritoneal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) DK (Trial now transitioned) FI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-000228-33 Sponsor Protocol Number: CE/17-12-06 Start Date*: Information not available in EudraCT
    Sponsor Name:CHU Saint-Pierre
    Full Title: Prospective longitudinal study on immunogenicity, induction of cellular immune responses and safety of vaccination against HPV with the 9valent vaccine in HIV-positive women
    Medical condition: Immune responses to administration of 9valent vaccine against HPV in HIV-positive women
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004848 10020180 HIV positive LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-001791-36 Sponsor Protocol Number: 310781 Start Date*: 2008-01-24
    Sponsor Name:Bayer Schering Pharma AG
    Full Title: A double-blind, randomized, placebo and active controlled, multicenter study to investigate efficacy and safety after oral administration of 2 and 3 mg ZK 283197, 1 mg 17ß-estradiol and placebo onc...
    Medical condition: Vasomotor symptoms (hot flushes)
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed) NL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-017282-35 Sponsor Protocol Number: 113617 Start Date*: 2010-07-07
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IIIb, open, multi-centre gynaecological extension study for the follow-up of a subset of HPV-015 study subjects
    Medical condition: GSK Biologicals' HPV-16/18 L1 VLP AS04 vaccine is indicated in females from 10 years of age onwards for the prevention of pre-malignant cervical lesions and cervical cancer causally related to Hum...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed) NL (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2014-005001-20 Sponsor Protocol Number: HIVECR Start Date*: 2015-05-21
    Sponsor Name:DR. ALEJANDRO SOUSA ESCANDÓN
    Full Title: CHEMO-RESECTION WITH HYPERTHERMIC INTRAVESICAL INSTILLATION (HIVEC-R) VS STANDARD TREATMENT IN PATIENTS WITH NMIBT: COMPARATIVE, PROSPECTIVE AND RANDOMIZED STUDY OF EFFICACY AND TOLERABILITY
    Medical condition: NMIBT
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-003131-16 Sponsor Protocol Number: 20584 Start Date*: 2021-01-25
    Sponsor Name:Bayer AG
    Full Title: A randomized, double-blind, open for active comparator, parallel-group, multicenter Phase 2b study to assess the efficacy and safety of three different doses of P2X3 antagonist (BAY 1817080) versus...
    Medical condition: Treatment of pain related to endometriosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004872 10014788 Endometriosis related pain LLT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed) CZ (Completed) SK (Completed) FI (Completed) NO (Completed) AT (Completed) LT (Completed) PL (Completed) BE (Completed) BG (Prematurely Ended) HU (Completed) GR (Completed) EE (Completed) LV (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000138-37 Sponsor Protocol Number: PERISCOPE Start Date*: 2013-09-25
    Sponsor Name:NKI-AvL
    Full Title: Treatment of PERItoneal dissemination in Stomach Cancer patients with cytOreductive surgery and hyperthermic intraPEritoneal chemotherapy
    Medical condition: Gastric cancer with peritoneal carcinomatosis or positive peritoneal cytology.
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004856 10017812 Gastric neoplasms malignant HLT
    16.0 10042613 - Surgical and medical procedures 10067093 Intraperitoneal hyperthermic chemotherapy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000608-16 Sponsor Protocol Number: 5466 Start Date*: 2011-12-21
    Sponsor Name:The Newcastle upon Tyne Hospitals NHS Foundation Trust [...]
    1. The Newcastle upon Tyne Hospitals NHS Foundation Trust
    2. The Newcastle upon Tyne Hospitals NHS Foundation Trust
    Full Title: To evaluate the safety and effectiveness of human ex vivo expanded autologous limbal stem cells for the treatment of unilateral total limbal stem cell deficiency
    Medical condition: unilateral total limbal stem cell deficiency
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-005748-12 Sponsor Protocol Number: 2012.761 Start Date*: 2013-04-26
    Sponsor Name:Hospices Civils de Lyon
    Full Title: D2 Resection and HIPEC (Hyperthermic intraperitoneal chemoperfusion) in locally advanced gastric carcinoma. A national randomized and multicentric phase III study
    Medical condition: Gastric adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10017770 Gastric carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000177-25 Sponsor Protocol Number: ATA129-EBV-205 Start Date*: 2021-01-04
    Sponsor Name:Atara Biotherapeutics, Inc.
    Full Title: An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects with Epstein-Barr Virus-associated Diseases
    Medical condition: • EBV+ primary imunodeficiency lymphoproliferative disease (LPD) • EBV+ LPD in the setting of acquired (non-congenital) immunodeficiency • EBV+ post-transplant LPD involving the central nervous ...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068349 Epstein-Barr virus associated lymphoproliferative disorder PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-008124-33 Sponsor Protocol Number: 112024 Start Date*: 2009-10-07
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IIIb, open, multi centre gynaecological extension study for follow-up of a subset of 580299/008 study subjects who were either cervical cytology negative and oncogenic HPV positive or pregn...
    Medical condition: GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine is indicated in females from 10 years of age onwards for the prevention of cervical cancer (squamous-cell carcinoma and adenocarcinoma) by protecting ...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: FI (Completed) ES (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-000059-38 Sponsor Protocol Number: 21810 Start Date*: 2021-11-17
    Sponsor Name:Bayer Consumer Care AG
    Full Title: A double-blind, randomized, placebo-controlled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms over 52 weeks in postmenopausal women.
    Medical condition: Vasomotor symptoms associated with menopause
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004872 10050903 Postmenopausal symptoms LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) ES (Completed) FI (Completed) DK (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-001888-40 Sponsor Protocol Number: DEP NHL-P 001.A Start Date*: 2006-07-24
    Sponsor Name:Mundipharma Research Ltd.
    Full Title: A phase II prospective non-comparative multicenter clinical trial to determine the efficacy and safety of intrathecal liposomal cytarabine (DepoCyte®) in preventing CNS-relapse in patients with agg...
    Medical condition: Prophylaxis of CNS relapse in adult patients with aggressive Non-Hodgkin-Lymphomas at risk for CNS metastasis
    Disease: Version SOC Term Classification Code Term Level
    7.0 10029547 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2017-003028-59 Sponsor Protocol Number: NL62684.091.17 Start Date*: 2018-06-06
    Sponsor Name:Radboud University Medical Centre
    Full Title: Treatment with Recombinant human Interleukin 1 receptor antagonist (Anakinra) in patients with Anaplastic Thyroid Cancer: a proof of concept study
    Medical condition: Anaplastic Thyroid Carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-003466-34 Sponsor Protocol Number: M06OVH Start Date*: 2006-12-14
    Sponsor Name:NKI-AVL
    Full Title: Phase III randomised clinical trial for stage III ovarian carcinoma randomising between secondary debulking surgery with or without hyperthermic intraperitoneal chemotherapy (OVHIPEC-I)
    Medical condition: ovarian carcinoma or peritoneal cancer (PPSC) or fallopian tube carcinoma FIGO Stage III
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-002429-37 Sponsor Protocol Number: NSGO-EC-9501 Amendment 2 Start Date*: 2004-11-17
    Sponsor Name:Nordic Society for Gynecologic Oncology
    Full Title: A randomized trial of adjuvant treatment with radiation plus chemotherapy versus radiation alone in high-risk endometrial carcinoma NSGO-EC-9501 Amendment 2.
    Medical condition: Endometrial cancer stage I-III radically operated with high-risk factors (high-grade and deep myometrial infiltration, or serous or clear cell histology) that will receive adjuvant treatment with r...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-001630-18 Sponsor Protocol Number: INOX-EGJ Start Date*: 2013-07-31
    Sponsor Name:Istituto Nazionale per lo Studio e la Cura dei Tumori di Napoli – Fondazione “G.Pascale”
    Full Title: Multicentre phase 2 study of neoadjuvant oxaliplatin and capecitabine followed by chemo-radiotherapy in patients with locally advanced carcinoma of esphago-gastric junction.
    Medical condition: Locally advanced carcinoma (squamous or adenocarcinoma) of the esophago-gastric junction Siewert type I and II
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10056267 Gastroesophageal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-003159-44 Sponsor Protocol Number: SOGUG-2017-A-IEC(VEJ)-1 Start Date*: 2018-09-27
    Sponsor Name:Spanish Oncology Genitourinary Group
    Full Title: Phase II trial of durvalumab (Medi4736) plus tremelimumab with concurrent radiotherapy in patients with localized muscle invasive bladder cancer treated with a selective bladder preservation approach
    Medical condition: Localized muscle invasive bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10022878 Invasive bladder cancer stage II LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 13 13:15:00 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA